Adoptive Immune-Cell Therapy for the Treatment of Neuroendocrine Carcinoma of the Uterine Cervix.
Anticancer Res
; 40(8): 4741-4748, 2020 Aug.
Article
en En
| MEDLINE
| ID: mdl-32727800
ABSTRACT
BACKGROUND/AIM:
We aimed to investigate the efficacy of immune-cell therapy in terms of the survival of patients with neuroendocrine carcinoma of the uterine cervix (NECC), which lacks standardized therapeutic approaches. PATIENTS ANDMETHODS:
We identified 17 patients who were diagnosed as having NECC and treated with immune-cell therapy. The clinical characteristics of these patients were extracted from their records and their overall survival was measured.RESULTS:
Of the 17 patients, two patients with early-stage NECC without recurrence and three patients with less than four treatments were excluded. The median survival times from the time of diagnosis and from the initial administration of immune-cell therapy were 49.7 and 24.4 months, respectively. The overall survival rates at 1, 2, and 5 years were 63.6%, 38.2%, and 25.5%, respectively. Long-term survival was observed in the patients with distant metastases.CONCLUSION:
The preliminary results of this retrospective study suggested the potential efficacy of immune-cell therapy for NECC.Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Neoplasias del Cuello Uterino
/
Cuello del Útero
/
Carcinoma Neuroendocrino
Tipo de estudio:
Observational_studies
/
Prognostic_studies
Límite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Anticancer Res
Año:
2020
Tipo del documento:
Article
País de afiliación:
Japón